In Vitro Models Of Liver And Pancreatic Cancer

$0.00

Clinical Trial Record

Return to Clinical Trials

Study Start

2015-07

Primary Completion (ESTIMATED)

2018-09

Study Completion

N/A

Enrollment (ESTIMATED)

Study Overview

In Vitro Models of Liver and Pancreatic Cancer

The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies. Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.

N/A

Cholangiocarcinoma
Hepatocellular Carcinoma
Pancreatic Neoplasm

GENETIC: Organoid in vitro culture

A093484

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2015-04-30	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2016-07-13
First Submitted that Met QC Criteria 2015-05-04	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2016-07-14
First Posted (ESTIMATED) 2015-05-07	Results First Posted N/A	Last Verified 2016-07

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.		3 years

Secondary Outcome Measures	Measure Description	Time Frame
Proportion of tumour-derived organoids that are genetically identical to the source tumour.		3 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Kourosh Saeb-Parsy, PhD, FRCS

Phone Number: (+44 1223 7) 68456

Email: ks10014@cam.ac.uk

Study Contact Backup

Name: Nikitas Georgakopoulos, BSc

Phone Number: 07554003700

Email: ng395@cam.ac.uk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

All adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent.

Patients aged <18 or those who are unable to give informed consent.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

The Gurdon Institute
Ann McLaren Laboratory of Regenerative Medicine

Investigators

PRINCIPAL_INVESTIGATOR: Kourosh Saeb-Parsy, PhD, FRCS, Cambridge Univeristy Hospitals

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record